Lung Ultrasound for Heart Failure Diagnosis in Primary Care.


Journal

Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 18 12 2019
revised: 20 04 2020
accepted: 30 04 2020
pubmed: 12 6 2020
medline: 19 8 2021
entrez: 12 6 2020
Statut: ppublish

Résumé

Lung ultrasound (LUS) is useful for diagnosing pulmonary congestion, but its value in primary care remains unclear. We investigated whether LUS improved diagnostic accuracy in outpatients with heart failure (HF) suspicion. LUS was performed on 2 anterior (A), 2 lateral (L), and 2 posterior (P) areas per hemithorax. An area was positive when ≥3 B-lines were observed. Two diagnostic criteria were used: for LUS-C1, 2 positive areas of 4 (A-L) on each hemithorax; and for LUS-C2, 2 positive areas of 6 (A-L-P) on each hemithorax. A cardiologist blinded to LUS validated HF diagnosis. 162 patients were included (age 75.6 ± 9.4 years, 70.4% women). Both LUS criteria, alone and combined with other HF diagnostic criteria, were accurate for identifying HF. LUS-C2 outperformed LUS-C1, showing remarkable specificity (0.99) and positive predictive value (0.92). LUS-C2, together with Framingham criteria, N-terminal pro-B-type natriuretic peptide, and electrocardiogram, added diagnostic value (area under the receiver operating characteristic curves 0.90 with LUS-C2 vs 0.84 without; P = .006). In the absence of N-terminal pro-B-type natriuretic peptide, LUS-C2 significantly reclassified one-third of patients above Framingham criteria and electrocardiogram (net reclassification improvement 0.65, 95% confidence interval 0.04-1.1). LUS was accurate enough to rule-in HF in a primary care setting. The accuracy of diagnostic workup for HF in primary care is enhanced by incorporating LUS, irrespective NT-proBNP availability.

Sections du résumé

BACKGROUND BACKGROUND
Lung ultrasound (LUS) is useful for diagnosing pulmonary congestion, but its value in primary care remains unclear. We investigated whether LUS improved diagnostic accuracy in outpatients with heart failure (HF) suspicion.
METHODS AND RESULTS RESULTS
LUS was performed on 2 anterior (A), 2 lateral (L), and 2 posterior (P) areas per hemithorax. An area was positive when ≥3 B-lines were observed. Two diagnostic criteria were used: for LUS-C1, 2 positive areas of 4 (A-L) on each hemithorax; and for LUS-C2, 2 positive areas of 6 (A-L-P) on each hemithorax. A cardiologist blinded to LUS validated HF diagnosis. 162 patients were included (age 75.6 ± 9.4 years, 70.4% women). Both LUS criteria, alone and combined with other HF diagnostic criteria, were accurate for identifying HF. LUS-C2 outperformed LUS-C1, showing remarkable specificity (0.99) and positive predictive value (0.92). LUS-C2, together with Framingham criteria, N-terminal pro-B-type natriuretic peptide, and electrocardiogram, added diagnostic value (area under the receiver operating characteristic curves 0.90 with LUS-C2 vs 0.84 without; P = .006). In the absence of N-terminal pro-B-type natriuretic peptide, LUS-C2 significantly reclassified one-third of patients above Framingham criteria and electrocardiogram (net reclassification improvement 0.65, 95% confidence interval 0.04-1.1).
CONCLUSIONS CONCLUSIONS
LUS was accurate enough to rule-in HF in a primary care setting. The accuracy of diagnostic workup for HF in primary care is enhanced by incorporating LUS, irrespective NT-proBNP availability.

Identifiants

pubmed: 32522554
pii: S1071-9164(19)31822-6
doi: 10.1016/j.cardfail.2020.04.019
pii:
doi:

Substances chimiques

Peptide Fragments 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

824-831

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None to declare.

Auteurs

Laura Conangla (L)

(1)Primary Care service Barcelonès Nord i Maresme, Badalona, Catalan Health Institute, Spain;; Heart Failure Unit and Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain;; Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Spain.

Mar Domingo (M)

(1)Primary Care service Barcelonès Nord i Maresme, Badalona, Catalan Health Institute, Spain;; Heart Failure Unit and Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain;; Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Spain.

Josep LupÓn (J)

Heart Failure Unit and Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain;; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain;; CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.

AsunciÓn Wilke (A)

(1)Primary Care service Barcelonès Nord i Maresme, Badalona, Catalan Health Institute, Spain;; Heart Failure Unit and Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain;; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.

Gladys JuncÀ (G)

Heart Failure Unit and Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Xavier Tejedor (X)

Biochemistry Service, University Hospital Germans Trias i Pujol, Badalona, Spain.

Giovanni Volpicelli (G)

Emergency Department, University Hospital San Luigi Gonzaga, Torino, Italy; and.

Lidia Evangelista (L)

Primary Care service Barcelona. Catalan Health Institute, Spain.

Guillem Pera (G)

Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Spain.

Pere Toran (P)

Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Spain.

Ariadna Mas (A)

(1)Primary Care service Barcelonès Nord i Maresme, Badalona, Catalan Health Institute, Spain;; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.

GermÁn Cediel (G)

Heart Failure Unit and Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

JosÉ MarÍa VerdÚ (JM)

Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Spain;; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain;; Primary Care service Barcelona. Catalan Health Institute, Spain.

Antoni Bayes-Genis (A)

Heart Failure Unit and Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain;; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain;; CIBERCV, Instituto de Salud Carlos III, Madrid, Spain;. Electronic address: abayesgenis@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH